Need help finding what you are looking for?
Contact Us
PUBLISHER: QYResearch | PRODUCT CODE: 1872258
PUBLISHER: QYResearch | PRODUCT CODE: 1872258
Circulating Tumor Cells - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
PUBLISHED:
PAGES: 129 Pages
DELIVERY TIME: 2-3 business days
SELECT AN OPTION
The global market for Circulating Tumor Cells was estimated to be worth US$ 2291 million in 2024 and is forecast to a readjusted size of US$ 8259 million by 2031 with a CAGR of 20.4% during the forecast period 2025-2031.
Circulating tumor cells are cancer cells that have detached from the tumor and are found at extremely low levels in the bloodstream. The value of capturing and counting CTCs is evolving as more research data is gathered about the utility of these markers in monitoring disease progression and potentially guiding personalized cancer therapy.
The circulating tumor cells (CTC) market is gaining significant traction due to its critical role in cancer detection, prognosis, and treatment monitoring. CTCs are cancer cells that have shed from the primary tumor into the bloodstream, offering a minimally invasive method for liquid biopsy. This technology is becoming increasingly important as it enables early detection, real-time disease monitoring, and personalized therapy selection without the need for invasive tissue biopsies. Key drivers include rising cancer incidence globally, advancements in microfluidics and next-generation sequencing, and growing demand for precision medicine solutions.
The market is witnessing innovations in CTC detection and isolation technologies, such as immunomagnetic separation, microfluidic devices, and PCR-based methods, which enhance accuracy and sensitivity. Pharmaceutical and diagnostic companies are heavily investing in research collaborations and clinical trials to integrate CTC analysis into cancer care protocols. Moreover, the integration of artificial intelligence and bioinformatics for interpreting complex CTC data is creating new opportunities for diagnostic and therapeutic advancements. As healthcare systems prioritize early cancer diagnosis and personalized treatment approaches, the adoption of CTC-based diagnostics is expected to grow significantly across clinical and research applications.
This report aims to provide a comprehensive presentation of the global market for Circulating Tumor Cells, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Circulating Tumor Cells by region & country, by Type, and by Application.
The Circulating Tumor Cells market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Circulating Tumor Cells.
Market Segmentation
By Company
- Menarini-Silicon Biosystems
- Qiagen (Adnagen)
- Advanced Cell Diagnostics
- ApoCell
- Epic Sciences
- Greiner Bio-one GmbH
- Cynvenio
- SurExamBio-Tech
- Fluxion Biosciences
- Ikonisys
- Hangzhou Watson Biotech
- Biocept
- CytoTrack
- Guangzhou Wondfo Biotech
- Celsee
- Clearbridge Biomedics
- ANGLE plc
Segment by Type
- CTC Enrichment
- CTC Detection
- CTC Analysis
Segment by Application
- Breast Cancer
- Prostate Cancer
- Colorectal Cancer
- Lung Cancer
- Others
By Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Circulating Tumor Cells company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Circulating Tumor Cells in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Circulating Tumor Cells in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
- 1.1 Circulating Tumor Cells Product Introduction
- 1.2 Global Circulating Tumor Cells Market Size Forecast (2020-2031)
- 1.3 Circulating Tumor Cells Market Trends & Drivers
- 1.3.1 Circulating Tumor Cells Industry Trends
- 1.3.2 Circulating Tumor Cells Market Drivers & Opportunity
- 1.3.3 Circulating Tumor Cells Market Challenges
- 1.3.4 Circulating Tumor Cells Market Restraints
- 1.4 Assumptions and Limitations
- 1.5 Study Objectives
- 1.6 Years Considered
2 Competitive Analysis by Company
- 2.1 Global Circulating Tumor Cells Players Revenue Ranking (2024)
- 2.2 Global Circulating Tumor Cells Revenue by Company (2020-2025)
- 2.3 Key Companies Circulating Tumor Cells Manufacturing Base Distribution and Headquarters
- 2.4 Key Companies Circulating Tumor Cells Product Offered
- 2.5 Key Companies Time to Begin Mass Production of Circulating Tumor Cells
- 2.6 Circulating Tumor Cells Market Competitive Analysis
- 2.6.1 Circulating Tumor Cells Market Concentration Rate (2020-2025)
- 2.6.2 Global 5 and 10 Largest Companies by Circulating Tumor Cells Revenue in 2024
- 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Circulating Tumor Cells as of 2024)
- 2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
- 3.1 Introduction by Type
- 3.1.1 CTC Enrichment
- 3.1.2 CTC Detection
- 3.1.3 CTC Analysis
- 3.2 Global Circulating Tumor Cells Sales Value by Type
- 3.2.1 Global Circulating Tumor Cells Sales Value by Type (2020 VS 2024 VS 2031)
- 3.2.2 Global Circulating Tumor Cells Sales Value, by Type (2020-2031)
- 3.2.3 Global Circulating Tumor Cells Sales Value, by Type (%) (2020-2031)
4 Segmentation by Application
- 4.1 Introduction by Application
- 4.1.1 Breast Cancer
- 4.1.2 Prostate Cancer
- 4.1.3 Colorectal Cancer
- 4.1.4 Lung Cancer
- 4.1.5 Others
- 4.2 Global Circulating Tumor Cells Sales Value by Application
- 4.2.1 Global Circulating Tumor Cells Sales Value by Application (2020 VS 2024 VS 2031)
- 4.2.2 Global Circulating Tumor Cells Sales Value, by Application (2020-2031)
- 4.2.3 Global Circulating Tumor Cells Sales Value, by Application (%) (2020-2031)
5 Segmentation by Region
- 5.1 Global Circulating Tumor Cells Sales Value by Region
- 5.1.1 Global Circulating Tumor Cells Sales Value by Region: 2020 VS 2024 VS 2031
- 5.1.2 Global Circulating Tumor Cells Sales Value by Region (2020-2025)
- 5.1.3 Global Circulating Tumor Cells Sales Value by Region (2026-2031)
- 5.1.4 Global Circulating Tumor Cells Sales Value by Region (%), (2020-2031)
- 5.2 North America
- 5.2.1 North America Circulating Tumor Cells Sales Value, 2020-2031
- 5.2.2 North America Circulating Tumor Cells Sales Value by Country (%), 2024 VS 2031
- 5.3 Europe
- 5.3.1 Europe Circulating Tumor Cells Sales Value, 2020-2031
- 5.3.2 Europe Circulating Tumor Cells Sales Value by Country (%), 2024 VS 2031
- 5.4 Asia Pacific
- 5.4.1 Asia Pacific Circulating Tumor Cells Sales Value, 2020-2031
- 5.4.2 Asia Pacific Circulating Tumor Cells Sales Value by Region (%), 2024 VS 2031
- 5.5 South America
- 5.5.1 South America Circulating Tumor Cells Sales Value, 2020-2031
- 5.5.2 South America Circulating Tumor Cells Sales Value by Country (%), 2024 VS 2031
- 5.6 Middle East & Africa
- 5.6.1 Middle East & Africa Circulating Tumor Cells Sales Value, 2020-2031
- 5.6.2 Middle East & Africa Circulating Tumor Cells Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
- 6.1 Key Countries/Regions Circulating Tumor Cells Sales Value Growth Trends, 2020 VS 2024 VS 2031
- 6.2 Key Countries/Regions Circulating Tumor Cells Sales Value, 2020-2031
- 6.3 United States
- 6.3.1 United States Circulating Tumor Cells Sales Value, 2020-2031
- 6.3.2 United States Circulating Tumor Cells Sales Value by Type (%), 2024 VS 2031
- 6.3.3 United States Circulating Tumor Cells Sales Value by Application, 2024 VS 2031
- 6.4 Europe
- 6.4.1 Europe Circulating Tumor Cells Sales Value, 2020-2031
- 6.4.2 Europe Circulating Tumor Cells Sales Value by Type (%), 2024 VS 2031
- 6.4.3 Europe Circulating Tumor Cells Sales Value by Application, 2024 VS 2031
- 6.5 China
- 6.5.1 China Circulating Tumor Cells Sales Value, 2020-2031
- 6.5.2 China Circulating Tumor Cells Sales Value by Type (%), 2024 VS 2031
- 6.5.3 China Circulating Tumor Cells Sales Value by Application, 2024 VS 2031
- 6.6 Japan
- 6.6.1 Japan Circulating Tumor Cells Sales Value, 2020-2031
- 6.6.2 Japan Circulating Tumor Cells Sales Value by Type (%), 2024 VS 2031
- 6.6.3 Japan Circulating Tumor Cells Sales Value by Application, 2024 VS 2031
- 6.7 South Korea
- 6.7.1 South Korea Circulating Tumor Cells Sales Value, 2020-2031
- 6.7.2 South Korea Circulating Tumor Cells Sales Value by Type (%), 2024 VS 2031
- 6.7.3 South Korea Circulating Tumor Cells Sales Value by Application, 2024 VS 2031
- 6.8 Southeast Asia
- 6.8.1 Southeast Asia Circulating Tumor Cells Sales Value, 2020-2031
- 6.8.2 Southeast Asia Circulating Tumor Cells Sales Value by Type (%), 2024 VS 2031
- 6.8.3 Southeast Asia Circulating Tumor Cells Sales Value by Application, 2024 VS 2031
- 6.9 India
- 6.9.1 India Circulating Tumor Cells Sales Value, 2020-2031
- 6.9.2 India Circulating Tumor Cells Sales Value by Type (%), 2024 VS 2031
- 6.9.3 India Circulating Tumor Cells Sales Value by Application, 2024 VS 2031
7 Company Profiles
- 7.1 Menarini-Silicon Biosystems
- 7.1.1 Menarini-Silicon Biosystems Profile
- 7.1.2 Menarini-Silicon Biosystems Main Business
- 7.1.3 Menarini-Silicon Biosystems Circulating Tumor Cells Products, Services and Solutions
- 7.1.4 Menarini-Silicon Biosystems Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)
- 7.1.5 Menarini-Silicon Biosystems Recent Developments
- 7.2 Qiagen (Adnagen)
- 7.2.1 Qiagen (Adnagen) Profile
- 7.2.2 Qiagen (Adnagen) Main Business
- 7.2.3 Qiagen (Adnagen) Circulating Tumor Cells Products, Services and Solutions
- 7.2.4 Qiagen (Adnagen) Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)
- 7.2.5 Qiagen (Adnagen) Recent Developments
- 7.3 Advanced Cell Diagnostics
- 7.3.1 Advanced Cell Diagnostics Profile
- 7.3.2 Advanced Cell Diagnostics Main Business
- 7.3.3 Advanced Cell Diagnostics Circulating Tumor Cells Products, Services and Solutions
- 7.3.4 Advanced Cell Diagnostics Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)
- 7.3.5 Advanced Cell Diagnostics Recent Developments
- 7.4 ApoCell
- 7.4.1 ApoCell Profile
- 7.4.2 ApoCell Main Business
- 7.4.3 ApoCell Circulating Tumor Cells Products, Services and Solutions
- 7.4.4 ApoCell Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)
- 7.4.5 ApoCell Recent Developments
- 7.5 Epic Sciences
- 7.5.1 Epic Sciences Profile
- 7.5.2 Epic Sciences Main Business
- 7.5.3 Epic Sciences Circulating Tumor Cells Products, Services and Solutions
- 7.5.4 Epic Sciences Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)
- 7.5.5 Epic Sciences Recent Developments
- 7.6 Greiner Bio-one GmbH
- 7.6.1 Greiner Bio-one GmbH Profile
- 7.6.2 Greiner Bio-one GmbH Main Business
- 7.6.3 Greiner Bio-one GmbH Circulating Tumor Cells Products, Services and Solutions
- 7.6.4 Greiner Bio-one GmbH Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)
- 7.6.5 Greiner Bio-one GmbH Recent Developments
- 7.7 Cynvenio
- 7.7.1 Cynvenio Profile
- 7.7.2 Cynvenio Main Business
- 7.7.3 Cynvenio Circulating Tumor Cells Products, Services and Solutions
- 7.7.4 Cynvenio Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)
- 7.7.5 Cynvenio Recent Developments
- 7.8 SurExamBio-Tech
- 7.8.1 SurExamBio-Tech Profile
- 7.8.2 SurExamBio-Tech Main Business
- 7.8.3 SurExamBio-Tech Circulating Tumor Cells Products, Services and Solutions
- 7.8.4 SurExamBio-Tech Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)
- 7.8.5 SurExamBio-Tech Recent Developments
- 7.9 Fluxion Biosciences
- 7.9.1 Fluxion Biosciences Profile
- 7.9.2 Fluxion Biosciences Main Business
- 7.9.3 Fluxion Biosciences Circulating Tumor Cells Products, Services and Solutions
- 7.9.4 Fluxion Biosciences Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)
- 7.9.5 Fluxion Biosciences Recent Developments
- 7.10 Ikonisys
- 7.10.1 Ikonisys Profile
- 7.10.2 Ikonisys Main Business
- 7.10.3 Ikonisys Circulating Tumor Cells Products, Services and Solutions
- 7.10.4 Ikonisys Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)
- 7.10.5 Ikonisys Recent Developments
- 7.11 Hangzhou Watson Biotech
- 7.11.1 Hangzhou Watson Biotech Profile
- 7.11.2 Hangzhou Watson Biotech Main Business
- 7.11.3 Hangzhou Watson Biotech Circulating Tumor Cells Products, Services and Solutions
- 7.11.4 Hangzhou Watson Biotech Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)
- 7.11.5 Hangzhou Watson Biotech Recent Developments
- 7.12 Biocept
- 7.12.1 Biocept Profile
- 7.12.2 Biocept Main Business
- 7.12.3 Biocept Circulating Tumor Cells Products, Services and Solutions
- 7.12.4 Biocept Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)
- 7.12.5 Biocept Recent Developments
- 7.13 CytoTrack
- 7.13.1 CytoTrack Profile
- 7.13.2 CytoTrack Main Business
- 7.13.3 CytoTrack Circulating Tumor Cells Products, Services and Solutions
- 7.13.4 CytoTrack Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)
- 7.13.5 CytoTrack Recent Developments
- 7.14 Guangzhou Wondfo Biotech
- 7.14.1 Guangzhou Wondfo Biotech Profile
- 7.14.2 Guangzhou Wondfo Biotech Main Business
- 7.14.3 Guangzhou Wondfo Biotech Circulating Tumor Cells Products, Services and Solutions
- 7.14.4 Guangzhou Wondfo Biotech Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)
- 7.14.5 Guangzhou Wondfo Biotech Recent Developments
- 7.15 Celsee
- 7.15.1 Celsee Profile
- 7.15.2 Celsee Main Business
- 7.15.3 Celsee Circulating Tumor Cells Products, Services and Solutions
- 7.15.4 Celsee Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)
- 7.15.5 Celsee Recent Developments
- 7.16 Clearbridge Biomedics
- 7.16.1 Clearbridge Biomedics Profile
- 7.16.2 Clearbridge Biomedics Main Business
- 7.16.3 Clearbridge Biomedics Circulating Tumor Cells Products, Services and Solutions
- 7.16.4 Clearbridge Biomedics Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)
- 7.16.5 Clearbridge Biomedics Recent Developments
- 7.17 ANGLE plc
- 7.17.1 ANGLE plc Profile
- 7.17.2 ANGLE plc Main Business
- 7.17.3 ANGLE plc Circulating Tumor Cells Products, Services and Solutions
- 7.17.4 ANGLE plc Circulating Tumor Cells Revenue (US$ Million) & (2020-2025)
- 7.17.5 ANGLE plc Recent Developments
8 Industry Chain Analysis
- 8.1 Circulating Tumor Cells Industrial Chain
- 8.2 Circulating Tumor Cells Upstream Analysis
- 8.2.1 Key Raw Materials
- 8.2.2 Raw Materials Key Suppliers
- 8.2.3 Manufacturing Cost Structure
- 8.3 Midstream Analysis
- 8.4 Downstream Analysis (Customers Analysis)
- 8.5 Sales Model and Sales Channels
- 8.5.1 Circulating Tumor Cells Sales Model
- 8.5.2 Sales Channel
- 8.5.3 Circulating Tumor Cells Distributors
9 Research Findings and Conclusion
10 Appendix
- 10.1 Research Methodology
- 10.1.1 Methodology/Research Approach
- 10.1.1.1 Research Programs/Design
- 10.1.1.2 Market Size Estimation
- 10.1.1.3 Market Breakdown and Data Triangulation
- 10.1.2 Data Source
- 10.1.2.1 Secondary Sources
- 10.1.2.2 Primary Sources
- 10.1.1 Methodology/Research Approach
- 10.2 Author Details
- 10.3 Disclaimer
List of Tables
- Table 1. Circulating Tumor Cells Market Trends
- Table 2. Circulating Tumor Cells Market Drivers & Opportunity
- Table 3. Circulating Tumor Cells Market Challenges
- Table 4. Circulating Tumor Cells Market Restraints
- Table 5. Global Circulating Tumor Cells Revenue by Company (2020-2025) & (US$ Million)
- Table 6. Global Circulating Tumor Cells Revenue Market Share by Company (2020-2025)
- Table 7. Key Companies Circulating Tumor Cells Manufacturing Base Distribution and Headquarters
- Table 8. Key Companies Circulating Tumor Cells Product Type
- Table 9. Key Companies Time to Begin Mass Production of Circulating Tumor Cells
- Table 10. Global Circulating Tumor Cells Companies Market Concentration Ratio (CR5 and HHI)
- Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Circulating Tumor Cells as of 2024)
- Table 12. Mergers & Acquisitions, Expansion Plans
- Table 13. Global Circulating Tumor Cells Sales Value by Type: 2020 VS 2024 VS 2031 (US$ Million)
- Table 14. Global Circulating Tumor Cells Sales Value by Type (2020-2025) & (US$ Million)
- Table 15. Global Circulating Tumor Cells Sales Value by Type (2026-2031) & (US$ Million)
- Table 16. Global Circulating Tumor Cells Sales Market Share in Value by Type (2020-2025)
- Table 17. Global Circulating Tumor Cells Sales Market Share in Value by Type (2026-2031)
- Table 18. Global Circulating Tumor Cells Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
- Table 19. Global Circulating Tumor Cells Sales Value by Application (2020-2025) & (US$ Million)
- Table 20. Global Circulating Tumor Cells Sales Value by Application (2026-2031) & (US$ Million)
- Table 21. Global Circulating Tumor Cells Sales Market Share in Value by Application (2020-2025)
- Table 22. Global Circulating Tumor Cells Sales Market Share in Value by Application (2026-2031)
- Table 23. Global Circulating Tumor Cells Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
- Table 24. Global Circulating Tumor Cells Sales Value by Region (2020-2025) & (US$ Million)
- Table 25. Global Circulating Tumor Cells Sales Value by Region (2026-2031) & (US$ Million)
- Table 26. Global Circulating Tumor Cells Sales Value by Region (2020-2025) & (%)
- Table 27. Global Circulating Tumor Cells Sales Value by Region (2026-2031) & (%)
- Table 28. Key Countries/Regions Circulating Tumor Cells Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
- Table 29. Key Countries/Regions Circulating Tumor Cells Sales Value, (2020-2025) & (US$ Million)
- Table 30. Key Countries/Regions Circulating Tumor Cells Sales Value, (2026-2031) & (US$ Million)
- Table 31. Menarini-Silicon Biosystems Basic Information List
- Table 32. Menarini-Silicon Biosystems Description and Business Overview
- Table 33. Menarini-Silicon Biosystems Circulating Tumor Cells Products, Services and Solutions
- Table 34. Revenue (US$ Million) in Circulating Tumor Cells Business of Menarini-Silicon Biosystems (2020-2025)
- Table 35. Menarini-Silicon Biosystems Recent Developments
- Table 36. Qiagen (Adnagen) Basic Information List
- Table 37. Qiagen (Adnagen) Description and Business Overview
- Table 38. Qiagen (Adnagen) Circulating Tumor Cells Products, Services and Solutions
- Table 39. Revenue (US$ Million) in Circulating Tumor Cells Business of Qiagen (Adnagen) (2020-2025)
- Table 40. Qiagen (Adnagen) Recent Developments
- Table 41. Advanced Cell Diagnostics Basic Information List
- Table 42. Advanced Cell Diagnostics Description and Business Overview
- Table 43. Advanced Cell Diagnostics Circulating Tumor Cells Products, Services and Solutions
- Table 44. Revenue (US$ Million) in Circulating Tumor Cells Business of Advanced Cell Diagnostics (2020-2025)
- Table 45. Advanced Cell Diagnostics Recent Developments
- Table 46. ApoCell Basic Information List
- Table 47. ApoCell Description and Business Overview
- Table 48. ApoCell Circulating Tumor Cells Products, Services and Solutions
- Table 49. Revenue (US$ Million) in Circulating Tumor Cells Business of ApoCell (2020-2025)
- Table 50. ApoCell Recent Developments
- Table 51. Epic Sciences Basic Information List
- Table 52. Epic Sciences Description and Business Overview
- Table 53. Epic Sciences Circulating Tumor Cells Products, Services and Solutions
- Table 54. Revenue (US$ Million) in Circulating Tumor Cells Business of Epic Sciences (2020-2025)
- Table 55. Epic Sciences Recent Developments
- Table 56. Greiner Bio-one GmbH Basic Information List
- Table 57. Greiner Bio-one GmbH Description and Business Overview
- Table 58. Greiner Bio-one GmbH Circulating Tumor Cells Products, Services and Solutions
- Table 59. Revenue (US$ Million) in Circulating Tumor Cells Business of Greiner Bio-one GmbH (2020-2025)
- Table 60. Greiner Bio-one GmbH Recent Developments
- Table 61. Cynvenio Basic Information List
- Table 62. Cynvenio Description and Business Overview
- Table 63. Cynvenio Circulating Tumor Cells Products, Services and Solutions
- Table 64. Revenue (US$ Million) in Circulating Tumor Cells Business of Cynvenio (2020-2025)
- Table 65. Cynvenio Recent Developments
- Table 66. SurExamBio-Tech Basic Information List
- Table 67. SurExamBio-Tech Description and Business Overview
- Table 68. SurExamBio-Tech Circulating Tumor Cells Products, Services and Solutions
- Table 69. Revenue (US$ Million) in Circulating Tumor Cells Business of SurExamBio-Tech (2020-2025)
- Table 70. SurExamBio-Tech Recent Developments
- Table 71. Fluxion Biosciences Basic Information List
- Table 72. Fluxion Biosciences Description and Business Overview
- Table 73. Fluxion Biosciences Circulating Tumor Cells Products, Services and Solutions
- Table 74. Revenue (US$ Million) in Circulating Tumor Cells Business of Fluxion Biosciences (2020-2025)
- Table 75. Fluxion Biosciences Recent Developments
- Table 76. Ikonisys Basic Information List
- Table 77. Ikonisys Description and Business Overview
- Table 78. Ikonisys Circulating Tumor Cells Products, Services and Solutions
- Table 79. Revenue (US$ Million) in Circulating Tumor Cells Business of Ikonisys (2020-2025)
- Table 80. Ikonisys Recent Developments
- Table 81. Hangzhou Watson Biotech Basic Information List
- Table 82. Hangzhou Watson Biotech Description and Business Overview
- Table 83. Hangzhou Watson Biotech Circulating Tumor Cells Products, Services and Solutions
- Table 84. Revenue (US$ Million) in Circulating Tumor Cells Business of Hangzhou Watson Biotech (2020-2025)
- Table 85. Hangzhou Watson Biotech Recent Developments
- Table 86. Biocept Basic Information List
- Table 87. Biocept Description and Business Overview
- Table 88. Biocept Circulating Tumor Cells Products, Services and Solutions
- Table 89. Revenue (US$ Million) in Circulating Tumor Cells Business of Biocept (2020-2025)
- Table 90. Biocept Recent Developments
- Table 91. CytoTrack Basic Information List
- Table 92. CytoTrack Description and Business Overview
- Table 93. CytoTrack Circulating Tumor Cells Products, Services and Solutions
- Table 94. Revenue (US$ Million) in Circulating Tumor Cells Business of CytoTrack (2020-2025)
- Table 95. CytoTrack Recent Developments
- Table 96. Guangzhou Wondfo Biotech Basic Information List
- Table 97. Guangzhou Wondfo Biotech Description and Business Overview
- Table 98. Guangzhou Wondfo Biotech Circulating Tumor Cells Products, Services and Solutions
- Table 99. Revenue (US$ Million) in Circulating Tumor Cells Business of Guangzhou Wondfo Biotech (2020-2025)
- Table 100. Guangzhou Wondfo Biotech Recent Developments
- Table 101. Celsee Basic Information List
- Table 102. Celsee Description and Business Overview
- Table 103. Celsee Circulating Tumor Cells Products, Services and Solutions
- Table 104. Revenue (US$ Million) in Circulating Tumor Cells Business of Celsee (2020-2025)
- Table 105. Celsee Recent Developments
- Table 106. Clearbridge Biomedics Basic Information List
- Table 107. Clearbridge Biomedics Description and Business Overview
- Table 108. Clearbridge Biomedics Circulating Tumor Cells Products, Services and Solutions
- Table 109. Revenue (US$ Million) in Circulating Tumor Cells Business of Clearbridge Biomedics (2020-2025)
- Table 110. Clearbridge Biomedics Recent Developments
- Table 111. ANGLE plc Basic Information List
- Table 112. ANGLE plc Description and Business Overview
- Table 113. ANGLE plc Circulating Tumor Cells Products, Services and Solutions
- Table 114. Revenue (US$ Million) in Circulating Tumor Cells Business of ANGLE plc (2020-2025)
- Table 115. ANGLE plc Recent Developments
- Table 116. Key Raw Materials Lists
- Table 117. Raw Materials Key Suppliers Lists
- Table 118. Circulating Tumor Cells Downstream Customers
- Table 119. Circulating Tumor Cells Distributors List
- Table 120. Research Programs/Design for This Report
- Table 121. Key Data Information from Secondary Sources
- Table 122. Key Data Information from Primary Sources
List of Figures
- Figure 1. Circulating Tumor Cells Product Picture
- Figure 2. Global Circulating Tumor Cells Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
- Figure 3. Global Circulating Tumor Cells Sales Value (2020-2031) & (US$ Million)
- Figure 4. Circulating Tumor Cells Report Years Considered
- Figure 5. Global Circulating Tumor Cells Players Revenue Ranking (2024) & (US$ Million)
- Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Circulating Tumor Cells Revenue in 2024
- Figure 7. Circulating Tumor Cells Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
- Figure 8. CTC Enrichment Picture
- Figure 9. CTC Detection Picture
- Figure 10. CTC Analysis Picture
- Figure 11. Global Circulating Tumor Cells Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million)
- Figure 12. Global Circulating Tumor Cells Sales Value Market Share by Type, 2024 & 2031
- Figure 13. Product Picture of Breast Cancer
- Figure 14. Product Picture of Prostate Cancer
- Figure 15. Product Picture of Colorectal Cancer
- Figure 16. Product Picture of Lung Cancer
- Figure 17. Product Picture of Others
- Figure 18. Global Circulating Tumor Cells Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
- Figure 19. Global Circulating Tumor Cells Sales Value Market Share by Application, 2024 & 2031
- Figure 20. North America Circulating Tumor Cells Sales Value (2020-2031) & (US$ Million)
- Figure 21. North America Circulating Tumor Cells Sales Value by Country (%), 2024 VS 2031
- Figure 22. Europe Circulating Tumor Cells Sales Value, (2020-2031) & (US$ Million)
- Figure 23. Europe Circulating Tumor Cells Sales Value by Country (%), 2024 VS 2031
- Figure 24. Asia Pacific Circulating Tumor Cells Sales Value, (2020-2031) & (US$ Million)
- Figure 25. Asia Pacific Circulating Tumor Cells Sales Value by Region (%), 2024 VS 2031
- Figure 26. South America Circulating Tumor Cells Sales Value, (2020-2031) & (US$ Million)
- Figure 27. South America Circulating Tumor Cells Sales Value by Country (%), 2024 VS 2031
- Figure 28. Middle East & Africa Circulating Tumor Cells Sales Value, (2020-2031) & (US$ Million)
- Figure 29. Middle East & Africa Circulating Tumor Cells Sales Value by Country (%), 2024 VS 2031
- Figure 30. Key Countries/Regions Circulating Tumor Cells Sales Value (%), (2020-2031)
- Figure 31. United States Circulating Tumor Cells Sales Value, (2020-2031) & (US$ Million)
- Figure 32. United States Circulating Tumor Cells Sales Value by Type (%), 2024 VS 2031
- Figure 33. United States Circulating Tumor Cells Sales Value by Application (%), 2024 VS 2031
- Figure 34. Europe Circulating Tumor Cells Sales Value, (2020-2031) & (US$ Million)
- Figure 35. Europe Circulating Tumor Cells Sales Value by Type (%), 2024 VS 2031
- Figure 36. Europe Circulating Tumor Cells Sales Value by Application (%), 2024 VS 2031
- Figure 37. China Circulating Tumor Cells Sales Value, (2020-2031) & (US$ Million)
- Figure 38. China Circulating Tumor Cells Sales Value by Type (%), 2024 VS 2031
- Figure 39. China Circulating Tumor Cells Sales Value by Application (%), 2024 VS 2031
- Figure 40. Japan Circulating Tumor Cells Sales Value, (2020-2031) & (US$ Million)
- Figure 41. Japan Circulating Tumor Cells Sales Value by Type (%), 2024 VS 2031
- Figure 42. Japan Circulating Tumor Cells Sales Value by Application (%), 2024 VS 2031
- Figure 43. South Korea Circulating Tumor Cells Sales Value, (2020-2031) & (US$ Million)
- Figure 44. South Korea Circulating Tumor Cells Sales Value by Type (%), 2024 VS 2031
- Figure 45. South Korea Circulating Tumor Cells Sales Value by Application (%), 2024 VS 2031
- Figure 46. Southeast Asia Circulating Tumor Cells Sales Value, (2020-2031) & (US$ Million)
- Figure 47. Southeast Asia Circulating Tumor Cells Sales Value by Type (%), 2024 VS 2031
- Figure 48. Southeast Asia Circulating Tumor Cells Sales Value by Application (%), 2024 VS 2031
- Figure 49. India Circulating Tumor Cells Sales Value, (2020-2031) & (US$ Million)
- Figure 50. India Circulating Tumor Cells Sales Value by Type (%), 2024 VS 2031
- Figure 51. India Circulating Tumor Cells Sales Value by Application (%), 2024 VS 2031
- Figure 52. Circulating Tumor Cells Industrial Chain
- Figure 53. Circulating Tumor Cells Manufacturing Cost Structure
- Figure 54. Channels of Distribution (Direct Sales, and Distribution)
- Figure 55. Bottom-up and Top-down Approaches for This Report
- Figure 56. Data Triangulation
- Figure 57. Key Executives Interviewed
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.